Does lurbinectedin cause hair loss?
Lurbinectedin ( Zepzelca), used for metastatic small cell lung cancer, lists alopecia (hair loss) as a common side effect in clinical trials, affecting 20-35% of patients depending on dose and combination therapy.[1][2] It's typically mild to moderate and reversible after treatment ends, but not all patients experience it.
Can you prevent hair loss from lurbinectedin?
No proven preventative measures exist specifically for lurbinectedin's hair loss. Unlike chemotherapy agents targeting rapidly dividing cells (e.g., taxanes), lurbinectedin inhibits transcription via DNA binding, with hair loss linked to follicular damage rather than direct cytotoxicity.[3] Standard scalp cooling (cold caps) used for some chemotherapies shows no reliable efficacy here, as trials exclude it and data is lacking.[1][4]
What management options do patients use?
- Scalp cooling trials: Limited anecdotal reports; not recommended routinely due to insufficient evidence for this drug.[4]
- Topical minoxidil: Some oncologists suggest 5% foam starting early in treatment to promote regrowth, though not studied specifically for lurbinectedin.[5]
- Nutritional support: Biotin, iron, or protein supplements if deficiencies contribute, but only under medical guidance to avoid interactions.[2]
Dermatologists often monitor and prescribe these post-onset rather than preventively.
How does lurbinectedin hair loss compare to other lung cancer drugs?
Less severe than platinum-based chemo (e.g., cisplatin: 50-80% alopecia) or topotecan (40-60%), but similar to irinotecan combos.[1][6] Keytruda (pembrolizumab) monotherapy rarely causes it (<5%).[7]
When does hair regrow after stopping?
Regrowth starts 1-3 months post-treatment in most cases, reaching baseline by 6 months.[2] Persistent loss is rare.
[1]: Zepzelca prescribing information, Jazz Pharmaceuticals. https://www.zepzelca.com/
[2]: FDA label for lurbinectedin. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[3]: Mechanism review, Clinical Cancer Research (2021). https://pubmed.ncbi.nlm.nih.gov/33500254/
[4]: ASCO guidelines on chemotherapy-induced alopecia. https://ascopubs.org/doi/10.1200/JCO.20.02727
[5]: Oncology nursing society alopecia management. https://www.ons.org/
[6]: Small cell lung cancer trial data, NEJM (2019). https://www.nejm.org/doi/full/10.1056/NEJMoa1912921
[7]: Keytruda label. https://www.keytruda.com/